23
views
0
recommends
+1 Recommend
2 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Decreased SIRT1 expression in the peripheral blood of patients with Graves’ disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          SIRT1, a class III histone/protein deacetylase (HDAC), has been associated with autoimmune diseases. There is a paucity of data about the role of SIRT1 in Graves’ disease. The aim of this study was to investigate the role of SIRT1 in the pathogenesis of GD. Here, we showed that SIRT1 expression and activity were significantly decreased in GD patients compared with healthy controls. The NF-κB pathway was activated in the peripheral blood of GD patients. The reduced SIRT1 levels correlated strongly with clinical parameters. In euthyroid patients, SIRT1 expression was markedly upregulated and NF-κB downstream target gene expression was significantly reduced. SIRT1 inhibited the NF-κB pathway activity by deacetylating P65. These results demonstrate that reduced SIRT1 expression and activity contribute to the activation of the NF-κB pathway and may be involved in the pathogenesis of GD.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Mammalian sirtuins: biological insights and disease relevance.

          Aging is accompanied by a decline in the healthy function of multiple organ systems, leading to increased incidence and mortality from diseases such as type II diabetes mellitus, neurodegenerative diseases, cancer, and cardiovascular disease. Historically, researchers have focused on investigating individual pathways in isolated organs as a strategy to identify the root cause of a disease, with hopes of designing better drugs. Studies of aging in yeast led to the discovery of a family of conserved enzymes known as the sirtuins, which affect multiple pathways that increase the life span and the overall health of organisms. Since the discovery of the first known mammalian sirtuin, SIRT1, 10 years ago, there have been major advances in our understanding of the enzymology of sirtuins, their regulation, and their ability to broadly improve mammalian physiology and health span. This review summarizes and discusses the advances of the past decade and the challenges that will confront the field in the coming years.
            • Record: found
            • Abstract: found
            • Article: not found

            Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network.

            The PGC-1 family of regulated coactivators, consisting of PGC-1α, PGC-1β and PRC, plays a central role in a regulatory network governing the transcriptional control of mitochondrial biogenesis and respiratory function. These coactivators target multiple transcription factors including NRF-1, NRF-2 and the orphan nuclear hormone receptor, ERRα, among others. In addition, they themselves are the targets of coactivator and co-repressor complexes that regulate gene expression through chromatin remodeling. The expression of PGC-1 family members is modulated by extracellular signals controlling metabolism, differentiation or cell growth and in some cases their activities are known to be regulated by post-translational modification by the energy sensors, AMPK and SIRT1. Recent gene knockout and silencing studies of many members of the PGC-1 network have revealed phenotypes of wide ranging severity suggestive of complex compensatory interactions or broadly integrative functions that are not exclusive to mitochondrial biogenesis. The results point to a central role for the PGC-1 family in integrating mitochondrial biogenesis and energy production with many diverse cellular functions. This article is part of a Special Issue entitled: Mitochondria and Cardioprotection. Copyright © 2010 Elsevier B.V. All rights reserved.
              • Record: found
              • Abstract: found
              • Article: not found

              Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.

              The tumor suppressor p53 exerts antiproliferation effects through its ability to function as a sequence-specific DNA-binding transcription factor. Here, we demonstrate that p53 can be modified by acetylation both in vivo and in vitro. Remarkably, the site of p53 that is acetylated by its coactivator, p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA binding. Furthermore, the acetylation of p53 can dramatically stimulate its sequence-specific DNA-binding activity, possibly as a result of an acetylation-induced conformational change. These observations clearly indicate a novel pathway for p53 activation and, importantly, provide an example of an acetylation-mediated change in the function of a nonhistone regulatory protein. These results have significant implications regarding the molecular mechanisms of various acetyltransferase-containing transcriptional coactivators whose primary targets have been presumed to be histones.

                Author and article information

                Journal
                J Endocrinol
                J. Endocrinol
                JOE
                The Journal of Endocrinology
                Bioscientifica Ltd (Bristol )
                0022-0795
                1479-6805
                August 2020
                02 June 2020
                : 246
                : 2
                : 161-173
                Affiliations
                [1 ]Shanghai National Clinical Research Center for Endocrine and Metabolic Diseases , Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Institute of EndocrineRuijin Hospital, Shanghai Jiao-Tong University School of Medicine, China
                [2 ]Division of Endocrinology and Metabolism , Department of Internal Medicine, RenJi Hospital, Shanghai Jiao-Tong University School of Medicine, Pudong, Shanghai, China
                [3 ]Reproductive Medicine Center , Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Science, Guangzhou, China
                [4 ]Department of Endocrinology and Metabolism , Shanghai Ninth People’s Hospital, Affiliated Shanghai Jiao-Tong University School of Medicine, Shanghai, China
                Author notes
                Correspondence should be addressed to D Lin and S Wang: lindongping2005@ 123456126.com or shuwang999@ 123456hotmail.com

                *(Q Yin and L Shen contributed equally to this work)

                Article
                JOE-19-0501
                10.1530/JOE-19-0501
                7354706
                32485674
                83f34e61-6640-44f5-9bd9-75d8469b9a4f
                © 2020 The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 13 May 2020
                : 02 June 2020
                Categories
                Research

                Endocrinology & Diabetes
                thyroid,graves’ disease,sirt1,nf-κb
                Endocrinology & Diabetes
                thyroid, graves’ disease, sirt1, nf-κb

                Comments

                Comment on this article

                Related Documents Log